Leo Pharma refinances loans and links costs to sustainability targets
Existing loans have been refinanced by Leo Pharma, which has also gained the option of borrowing an additional DKK 1.5bn (USD 230.8m) to execute its growth strategy. A new interest mechanism that links borrowing costs to Leo Pharma's progress toward certain sustainability targets has been implemented.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Leo Pharma has until 2027 to repay loans of more than DKK 11bn (USD 1.7bn) – and has gained access to another unused credit facility of DKK 1.5 (USD 230.8m), it reports in a press release on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WS Audiology joins Science Based Targets initiative
For subscribers
.jpg&w=384&q=75)
